Results 51 to 60 of about 109,974 (359)
Antihypertensive agents safety during pregnancy
RUDN Journal of Medicine, 2011 The article discusses pregnancy course and labor outcomes in women with chronic hypertension. We divided all pregnant into two groups in dependence on the kind of antihypertensive treatment. The main group treatment was nebivalol monotherapy, the control
E V Karpova +6 more
doaj
PRESCRIBING OF ANTIHYPERTENSIVE AGENTS IN PUBLIC PRIMARY CARE CLINICS – IS IT IN ACCORDANCE WITH CURRENT EVIDENCE? [PDF]
Malaysian Family Physician, 2010 Background: Large population surveys in Malaysia have consistently shown minimal improvement of blood pressure control rates over the last 10 years. Poor adherence to antihypertensive medication has been recognized as a major reason for poor control of ...
SAJARI J +7 more
doaj
British Journal of Clinical Pharmacology, EarlyView.Aims Trial run‐in phases are sometimes used to select adherent participants as a strategy to enrich trials, but the methods employed lack clear regulatory guidance and there are concerns about the transparency of reporting. This review aims to characterize the methods used for adherence measurement and public reporting of run‐in studies.
Non Davies +3 more
wiley +1 more source
CURRENT TARGET OF ANTIHYPERTENSIVE THERAPY. DATA FROM CLINICAL TRIALS. PART 2
Рациональная фармакотерапия в кардиологии, 2015 Arterial hypertension (HT) takes leading position in the structure of morbidity and mortality among the cardiovascular diseases in the economically developed and developing countries of the world.
V. V. Popov, N. A. Bulanov, G. G. Ivanov
doaj +3 more sources
Changes in kidney function in a population with essential hypertension in real life settings [PDF]
, 2017 Introduction. Hypertension has been identified as one of the commonest modifiable determinants for chronic kidney disease progression. A variety of antihypertensive drugs are available and their effect on kidney function has been investigated by a ...
Haidich, Anna-Bettina +6 more
core
Relationship between cardiovascular risk and lipid testing in one health care system: a retrospective cohort study. [PDF]
, 2015 BackgroundThe US Preventive Services Taskforce (USPSTF) recommends routine lipid screening beginning age 35 for men [1]. For women age 20 and older, as well as men age 20-34, screening is recommended if cardiovascular risk factors are present.
Anderson, Melissa L +6 more
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source
Palliative Medicine ReportsBackground: Treatment with antihypertensives in patients with advanced cancer is often continued until very late in the disease trajectory, despite a considerable risk of hypotension.
Linda Björkhem-Bergman +3 more
doaj +1 more source
Pharmacogenetic Tests in the Nephrological Clinic
Počki, 2016 Selection of antihypertensive agents using pharmacogenetic tests and individual tolerance is essential in practical nephrology. Antihypertensive first-line drugs are metabolized through various CYP isoforms (CYP2D6, CYP2C9, CYP2C19 and CYP3A4/5).
D.D. Ivanov, O.O. Melnik
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.People accessing aged care services are increasingly older and often experience multimorbidity and polypharmacy, which puts them at risk of medication‐related harm. Quality indicators (QIs) can assist with monitoring, benchmarking and informing initiatives to reduce medication‐related harm.
Daria S. Gutteridge +20 more
wiley +1 more source